Reza Zadno Sells 5,475 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

PROCEPT BioRobotics Stock Up 0.4 %

Shares of PROCEPT BioRobotics stock traded up $0.23 on Friday, reaching $58.10. The company's stock had a trading volume of 666,081 shares, compared to its average volume of 727,334. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of -29.79 and a beta of 1.05. The firm's fifty day simple moving average is $67.15 and its two-hundred day simple moving average is $78.34. PROCEPT BioRobotics Co. has a 52 week low of $45.56 and a 52 week high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The business had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. Equities analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Remove Ads

Institutional Trading of PROCEPT BioRobotics

A number of institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of PROCEPT BioRobotics by 19.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,391 shares of the company's stock worth $11,224,000 after purchasing an additional 22,931 shares in the last quarter. Voloridge Investment Management LLC grew its holdings in shares of PROCEPT BioRobotics by 60.4% in the fourth quarter. Voloridge Investment Management LLC now owns 454,374 shares of the company's stock worth $36,586,000 after acquiring an additional 171,029 shares during the period. Two Sigma Advisers LP grew its holdings in shares of PROCEPT BioRobotics by 237.1% in the fourth quarter. Two Sigma Advisers LP now owns 90,000 shares of the company's stock worth $7,247,000 after acquiring an additional 63,300 shares during the period. Two Sigma Investments LP grew its holdings in shares of PROCEPT BioRobotics by 91.0% in the fourth quarter. Two Sigma Investments LP now owns 353,716 shares of the company's stock worth $28,481,000 after acquiring an additional 168,505 shares during the period. Finally, Summit Partners Public Asset Management LLC grew its holdings in shares of PROCEPT BioRobotics by 1.6% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 551,767 shares of the company's stock worth $44,428,000 after acquiring an additional 8,721 shares during the period. Institutional investors own 89.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PRCT shares. Truist Financial restated a "buy" rating and issued a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Morgan Stanley lowered their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $94.29.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).